Angka Kejadian dan Faktor yang Memengaruhi Potensi Interaksi Obat dengan Obat pada Pasien Leukemia Akut Anak yang Menjalani Rawat Inap

Sri Wulandah Fitriani, Rina Mutiara, Amarila Malik, Murti Andriastuti

Sari


Latar belakang. Risiko terjadinya potensi interaksi obat dengan obat (PIOO) pada pasien leukemia akut akibat pemberian terapi multidrug cukup tinggi.
Tujuan. Mengetahui angka kejadian dan faktor yang memengaruhi PIOO pada subjek penelitian.
Metode. Penelitian dilakukan dengan metode potong lintang. Pengambilan data dilakukan secara retrospektif terhadap pasien leukemia akut pada anak yang menjalani rawat inap di RSCM pada Januari – Desember 2014. Identifikasi PIOO dilakukan menggunakan perangkat lunak Micromedex Drug Reax®.
Hasil. Didapat 96 subjek yang memenuhi kriteria penelitian. Subjek berpotensi mengalami PIOO 41,6% dengan tingkat keparahan kontraindikasi (4,70%), berat (60,70%), dan sedang (34,60%). Jenis PIOO paling sering adalah deksametason dan flukonazol yang berpotensi meningkatkan paparan glukokortikoid. Terdapat perbedaan bermakna pada faktor usia (p=0,037), lama hari rawat (p=0,000), dan rerata jumlah obat (p=0,000), sedangkan komorbiditas tidak menunjukkan perbedaan (p=0,082).
Kesimpulan. Angka kejadian PIOO pasien leukemia akut pada anak yang menjalani rawat inap di RSCM adalah 41,6%. Faktor usia, lama hari rawat, dan rerata jumlah obat berpengaruh signifikan terhadap kejadian PIOO dengan nilai OR 1,8 terhadap pasien berusia >7 tahun, 6,3 terhadap pasien dengan lama hari rawat >7 hari, dan 5,3 terhadap pasien dengan rerata pemberian >4 obat per
hari. Sari

 


Kata Kunci


interaksi obat; kemoterapi; leukemia akut; micromedex; pediatrik

Teks Lengkap:

PDF

Referensi


American Cancer Society. Leukemia childhood overview. Atlanta: American Cancer Society; 2013.

Meidiana B. Analisis faktor kejadian relapse pada anak dengan leukemia di RSCM [tesis]. Depok: Fakultas Ilmu Keperawatan Universitas Indonesia, 2012.

American Cancer Society. Survival rates for childhood leukemias. American Cancer Soc [serial online] Feb 2016 [disitasi 9 Jul 2016]; 2016. Didapat dari: URL: http://www.cancer.org/cancer/leukemiainchildren/detailedguide/

childhood-leukemia-survival-rates.

Permatasari E, Windiastuti E, Satari HI. Survival and prognostics factors of childhood acute lymphoblastic leukemia. Paediatrica Indonesiana 2009;49: 365-71.

Cremades J, Gonzalo M, Arrebola I. Relationship between drug interactions and drug-related negative clinical outcomes. Pharmacy Practice 2009;7:34-9.

Langerova P, Prokes M, Konvalinka M, Furstova J, Urbanek K. Incidence of potential drug interactions in medication prescriptions for children and adolescents in the University Hospital Olomouc, Czech Republic. Europe J Pediatric 2013;172:631-8.

Bhagavathula AS, Berhanie A, Tigitsu H, Abraham Y, Getachew Y, Khan TM, Unakal C. Prevalence of potential drug-drug interactions among internal medicine ward in University of Gondar Teaching Hospital, Ethiopia. Asian Pacific J Tropical Biomedicine 2014;4:S204-8.

Hadjibabaie M, Badri S, Ataei S, Moslehi AH, Karimzadeh I, Ghavamzadeh A. Potential drug-drug interactions at a referral hematology-oncology ward in 9. Iran: a cross-sectional study. Cancer Chemotheraphy Pharmacology 2013;71:1619-27.

Ussai S, Petelin R, Giordano A, Malinconico M, Cirillo D, Pentimalli F. A pilot study on the impact of known drug-drug interactions in cancer patients. J Experimental & Clinical Cancer Research 2015;34:1-6.

Becker M, Kallewaard M, Caspers PWJ, Visser LE, Hubert GML, Stricker B. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiology

and Drug Safety 2007;16:641-51.

Skvrce NM, Sarinic VM, Mucalo I, Krnic D, Bozina N, Tomic S. Adverse drug reactions caused by drugdrug interactions reported to Croatian Agency for medicinal products and medical devices: a retrospective observational study. Croatian Medical J 2011;52:604-14.

Haidar C, Jeha S. Review: drug interactions in childhood cancer. Lancet Oncology 2010;12:92-9.

Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T. Fatal adverse drug events: the paradox of drug treatment. J Internal Medicine 2001;250:327-41.

Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J National Cancer Institute 2007;99:592-600.

Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children’s hospitals. Pediatrics 2015;135:e99-e108.

Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a brazilian teaching hospital. Clinics 2006;61:515-20.

Van Leeuwen, Swart, Boven, Boom, Schuitenmaker, Hugtenburg. Potential drug interactions in cancer theraphy: a prevalence study using an advanced screening method. Annals of Oncology 2011;22:2334-41.

Kaur SP, Rao R, Nanda S. Amoxicillin: A broad spectrum antibiotic. International J Pharmacy and Pharmaceutical Sciences 2011;3:30-7.

Fredj NB, Aouam K, Chaabane A, Toumi A, Rhomdhane FB, Bhoughattas N, Chakroun M. Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. British J Clinical Pharmacology 2010;70: 273-76.

Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in cardiac and cardiothoracic intensive care units. Drug Safety 2010;33:879-88.

Vitry AI. Comparative assessment of four drug interaction compendia. British J Clinical Pharmacology 2006;63:709-14.

Schnell FM. Chemotherapy induced nausea and vomiting: the importance of acute antiemetic control. The Oncologist 2003;8:187-98.

Dewoto HR, Louisa M. Serotonin, obat serotonergik, dan obat antiserotonergik. Dalam: Gunawan SG, Setiabudy R, Nafrialdi, Elysabeth, penyunting. Farmakologi dan terapi. Edisi kelima. Jakarta: Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas

Indonesia;2007:h.268-97.

Espinosa FP, Carrasco D, Soler F, Merino R, Nieto DR, Miro E. Pharmacoepidemiological study of drug-drug interactions in oncohematological pediatric patients. International J Clinical Pharmacy 2014;36:1160-9.

Hafermann MJ, Namdar R, Seibold GE, Lee R. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthcare and Patient Safety 2011;3:53-8.

Chan A, Yap KY, Koh D, Low XH, Cheung YT, Oncoinformatics

group. Electronic database to detect drugdrug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians. Pharmacoepidemiology and

Drug Safety 2011;20:939-47.




DOI: http://dx.doi.org/10.14238/sp18.2.2016.129-36

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc-sa4.footer##

Informasi Editorial:
Badan Penerbit Ikatan Dokter Anak Indonesia
Jl. Salemba I No 5, Jakarta 10430, Indonesia
Phone/Fax: +62-21-3912577
Email: editorial [at] saripediatri.org

Lisensi Creative Commons
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.